-
The Chinese market is promising, what are the localization strategies of foreign instrument companies?
Time of Update: 2023-02-01
14 pharmaceutical companies, including Dirui Medical, were investigated [ News Search ] [ Add to favorites ] [ Tell a friend ] [ Print this article ] [ Close Window ] Similar information January 7, 2022, Agilent announced that it will expand production and capabilities at its Shanghai manufacturing center, invest in expanding production of advanced technology products such as liquid chromatograph (LC), spectrometer, and mass spectrometer (MS) systems, and further enhance Agilent's manufacturing capabilities in China.
-
In 2023, the willingness of domestic innovative drugs to go overseas will continue to increase
Time of Update: 2023-02-01
In 2023, the willingness of domestic innovative drugs to go overseas will continue to increase (Image source; Pharma Network) Domestic innovation strength is increasingly recognized, and going overseas is accelerating Some time ago, Kelun Pharmaceutical reached an overseas rights authorization with Merck for 7 preclinical ADC drugs, with a total milestone of up to US$9.
-
The new coronavirus treatment drug monoravir capsules completed the first batch of import customs clearance in the Shanghai Waigaoqiao Free Trade Zone
Time of Update: 2023-02-01
The new coronavirus treatment drug monoravir capsules completed the first batch of import customs clearance in the Waigaoqiao Free Trade Zone in Shanghai on the 13th.
The new coronavirus treatment drug monoravir capsules completed the first batch of import customs clearance in the Waigaoqiao Free Trade Zone in Shanghai on the 13th.
-
Hundreds of millions of discounted interest loans help mass spectrometer procurement! Last month, the total amount of the mass spectrometer won the bid exceeded 1.1 billion
Time of Update: 2023-02-01
On September 7, 2022, the executive meeting of the State Council decided to impose a 2. 5% financial discount on loans for equipment renovation and renovation in some fields before December 31, and o
-
Notice on public solicitation of comments on the Catalogue of Reference Preparations for Chemical Generic Drugs (66th Batch) (Draft for Comments).
Time of Update: 2023-02-01
Center for Drug Evaluation, State Medical Products Administration January 09, 2023 Related attachments serial number Attachment name 1 The Catalogue of Reference Preparations for Chemical Generic Drugs (Batch 66) (Draft for Comments) .
-
Inventory of the 2022 Ministry of Science and Technology major scientific instrument research and development special project plan high-end instrument research and development
Time of Update: 2023-02-01
Innovation is the need for the development of science and technology and social production, which will promote the development and change of analytical chemistry. As an important tool for scientific
-
In 2023, "Golden Eye" is expected to return, and ophthalmic companies may maintain a high degree of prosperity
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Recently, some institutions pointed out that the current investment in the pharmaceutical sector will gradually return to the main business, focusing on consumer medical care.
js?cdnversion='+~(-new Date()/36e5)];Recently, some institutions pointed out that the current investment in the pharmaceutical sector will gradually return to the main business, focusing on consumer medical care.
-
In 2023, the leading companies of conventional vaccines may usher in a larger market increment
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Kangtai Biotechnology, a leading domestic vaccine company, released its 2022 performance forecast on the evening of January 10, and it is expected that the net profit attributable to shareholders of listed companies in 2022 will be a loss of 76 million yuan ~ 150 million yuan, down 106.
-
In order to get out of the "inner volume", domestic pharmaceutical company license-out will continue to be hot!
Time of Update: 2023-02-01
(Image source: Pharma Network) It is reported that the exclusive transfer right agreement contains the license terms negotiated between SignNova and AmMax. At the same time, in accordance with this agreement, the two parties will collaborate to complete the clinical trial application (IND) of the collaborative project and the design of the dose-escalation clinical study, which is expected to be submitted to the IND application in China and the United States in mid-2023.
-
Since January, the cumulative transaction turnover of the pharmaceutical industry has exceeded 10 billion, and Hengrui has "won the championship"
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Data show that as of January 15, a total of 1,871 large transactions have occurred in the A-share market since 2023, with a cumulative transaction volume of 2.
-
Notice on public solicitation of opinions on the "Technical Guidelines for the Research of Improved New Drugs of Traditional Chinese Medicine (Draft for Comments)"
Time of Update: 2023-02-01
Notice on public solicitation of opinions on the "Technical Guidelines for the Research of Improved New Drugs of Traditional Chinese Medicine (Draft for Comments)"Release date: 20230106 According to
-
Affected by the surge in demand for Paxlovid, Pfizer is ready to start production in China
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];A few days ago, Pfizer CEO Aberle said that the surge in demand for Paxlovid in the Chinese market has led to tight supply, and it is working with a Chinese contract drugmaker to prepare for local production.
-
In the "height" market of tens of billions of yuan, the product research and development of many pharmaceutical companies has ushered in new progress
Time of Update: 2023-02-01
Recently, Changchun High-tech issued the "Announcement on the Approval of New Indications of Recombinant Human Growth Hormone Injection of Holding Subsidiaries" (hereinafter referred to as the "Announcement"), and the approved and increased indication of the drug is prepubertal growth disorder caused by chronic kidney disease (CKD).
-
2022 inventory of 227 IND varieties declared for the first time for domestic Class 1 new drugs, Hengrui leading, Qilu, East Sunshine...
Time of Update: 2023-02-01
, is an innovative, oral small molecule HIF-2α inhibitor clinically intended for the treatment of patients with advanced solid tumors.
, is an innovative, oral small molecule HIF-2α inhibitor clinically intended for the treatment of patients with advanced solid tumors.
-
This week, a large number of domestic pharmaceutical companies announced that new drugs have been approved for clinical trials
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Recently, Saisheng Pharmaceutical issued an announcement that the company received the notice of approval of the supplementary application for clinical trial of humanized anti-VEGF monoclonal antibody injection issued by the National Medical Products Administration.
-
China's domestic small molecule new coronavirus treatment is undergoing clinical trials
Time of Update: 2023-02-01
drugs In the 10th edition of the new coronavirus infection diagnosis and treatment plan announced in China, antiviral treatment includes nematevir tablets/ritonavir tablets combination package (referred to as "Paxlovid"), azvudine tablets, monoclonal antibodies, intravenous COVID-19 human immunoglobulin, convalescent plasma of convalescent patients, etc.
-
The reform of DRG's payment method "traditional Chinese medicine" has achieved new results
Time of Update: 2023-01-06
As of the end of October 2022, a total of 1,829 designated medical institutions in 15 coordinated areas in Guangxi have implemented DRG payment, covering 87.
As of the end of October 2022, a total of 1,829 designated medical institutions in 15 coordinated areas in Guangxi have implemented DRG payment, covering 87.
-
The reform of DRG's payment method "traditional Chinese medicine" has achieved new results
Time of Update: 2023-01-06
As of the end of October 2022, a total of 1,829 designated medical institutions in 15 coordinated areas in Guangxi have implemented DRG payment, covering 87.
As of the end of October 2022, a total of 1,829 designated medical institutions in 15 coordinated areas in Guangxi have implemented DRG payment, covering 87.
-
Pharmaceutical equipment companies are working hard to sprint to the fourth quarter!
Time of Update: 2023-01-06
【Pharmaceutical Network Industry News】For pharmaceutical equipment companies, the fourth quarter is a key period to complete the annual target tasks, and there is no room for any relaxation. Recently,
-
Pharmaceutical equipment companies are working hard to sprint to the fourth quarter!
Time of Update: 2023-01-06
【Pharmaceutical Network Industry News】For pharmaceutical equipment companies, the fourth quarter is a key period to complete the annual target tasks, and there is no room for any relaxation. Recently,
